Abstract:Background Nicotinamide N -methyltransferase (NNMT) is overexpressed in various human tumors and involved in the development and progression of several carcinomas. In breast cancer, NNMT was found to be overexpressed in several cell lines. However, the clinical relevance of NNMT in breast cancer is not yet clear. Methods NNMT expression in breast carcinoma was examined by immunohistochemistry, and then, its relationship with patient clinicopathological characteristics was analyzed. The effects of NNMT on chemoresistance in breast cancer cells were assessed by cell viability, colony formation, and apoptosis assay. The NNMT, SIRT1, p53, and acetyl-p53 proteins, which are involved in NNMT-related chemoresistance, were examined by Western blotting. The SIRT1 mRNA was examined by real-time PCR, and its activity was measured by using the SIRT1 deacetylase fluorometric reagent kit. Results NNMT expression was significantly higher (53.9%) in breast carcinoma than in paracancerous tissues (10.0%) and breast hyperplasia (13.3%). A high level of NNMT expression correlated with poor survival and chemotherapy response in breast cancer patients who received chemotherapy. Ectopic overexpression of NNMT significantly inhibited the apoptotic cell death and suppression of colony formation induced by adriamycin and paclitaxel. Mechanistic studies revealed that NNMT overexpression increased SIRT1 expression and promoted its activity. Either inhibition of SIRT1 by EX527 or knockdown of SIRT1 by siRNA could reverse NNMT-mediated resistance to adriamycin and paclitaxel, which suggests that SIRT1 plays a critical role in NNMT-related chemoresistance in breast cancer. Conclusions The results of this study demonstrate a novel correlation between the NNMT expression level and patient survival, suggesting that NNMT has the potential to become a new prognostic biomarker to predict the treatment outcomes of the clinical chemotherapy in breast cancer. Moreover, targeting NNMT or downstream SIRT1 may represent a new therapeutic approach to improve the efficacy of breast cancer chemotherapy.

SIRT1 mediates breast cancer development and tumorigenesis controlled by estrogen-related receptor β

SIRT1 is involved in oncogenic signaling mediated by GPER in breast cancer

SIRT1 Facilitates Hepatocellular Carcinoma Metastasis by Promoting PGC-1α-mediated Mitochondrial Biogenesis.

Sirtuin 1 facilitates chemoresistance of pancreatic cancer cells by regulating adaptive response to chemotherapy-induced stress.

Nicotinamide N -methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization

Recent Advances of SIRT1 and Implications in Chemotherapeutics Resistance in Cancer.

SIRT1 Promotes Endometrial Tumor Growth by Targeting SREBP1 and Lipogenesis.

SIRT1: a Potential Tumour Biomarker and Therapeutic Target.

SIRT1 and gynecological malignancies

Oncogenic role of SIRT1 associated with tumor invasion, lymph node metastasis, and poor disease-free survival in triple negative breast cancer

SIRT1 promotes EMT, migration and invasion by regulating mTORC1/4E-BP1 in colorectal cancer

SIRT1 is involved in adrenocortical cancer growth and motility

Pharmacological and genetic perturbation establish SIRT5 as a promising target in breast cancer

Silent Information Regulator 1 Suppresses Epithelial-to-mesenchymal Transition in Lung Cancer Cells Via Its Regulation of Mitochondria Status

The Role of SIRT1 on DNA Damage Response and Epigenetic Alterations in Cancer

High Levels of SIRT1 Expression Enhance Tumorigenesis and Associate with a Poor Prognosis of Colorectal Carcinoma Patients

Expression of SIRT1 is Associated with Lymph Node Metastasis and Poor Prognosis in Both Operable Triple-Negative and Non-Triple-negative Breast Cancer

Sirtuin-1 Regulates Acinar-to-ductal Metaplasia and Supports Cancer Cell Viability in Pancreatic Cancer.

SIRT1 and Gynecological Malignancies (Review)

Sirtuin 1 Stimulates the Proliferation and the Expression of Glycolysis Genes in Pancreatic Neoplastic Lesions

Sirtuins as Key Regulators in Pancreatic Cancer: Insights into Signaling Mechanisms and Therapeutic Implications